.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Randomized evidence has shown that continuous glucose monitoring (CGM) can improve glycemic control in adults with type 2 diabetes treated with basal insulin, particularly when the technology is integrated into routine clinical follow-up. CGM provides trend information, time-in-range data and alerts that are not available from intermittent finger-stick measurements alone. For internists, this can change the conversation from a small number of isolated glucose readings to an ongoing profile of glycemic variability and treatment response. The value is greatest when patients understand how to interpret trends and clinicians have a plan for reviewing and acting on the data. CGM does not automatically improve outcomes if the information is not translated into treatment decisions, and access, affordability and digital literacy remain barriers. In older adults or patients with complex regimens, individualized alarm settings and education are particularly important. The broader significance is that diabetes technology increasingly functions as a clinical-management tool rather than merely a monitoring device. This aligns with APICON's focus on wearables and digital health, where the central question is how technology improves decisions and patient behavior rather than simply generating more data.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Randomized evidence has shown that continuous glucose monitoring (CGM) can improve glycemic control in adults with type 2 diabetes treated with basal insulin, particularly when the technology is integrated into routine clinical follow-up. CGM provides trend information, time-in-range data and alerts that are not available from intermittent finger-stick measurements alone. For internists, this can change the conversation from a small number of isolated glucose readings to an ongoing profile of glycemic variability and treatment response. The value is greatest when patients understand how to interpret trends and clinicians have a plan for reviewing and acting on the data. CGM does not automatically improve outcomes if the information is not translated into treatment decisions, and access, affordability and digital literacy remain barriers. In older adults or patients with complex regimens, individualized alarm settings and education are particularly important. The broader significance is that diabetes technology increasingly functions as a clinical-management tool rather than merely a monitoring device. This aligns with APICON's focus on wearables and digital health, where the central question is how technology improves decisions and patient behavior rather than simply generating more data.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
